ImmunoCellular Therapeutics Competitors

Wellness Center USA (OTCMKTS:WCUI) and ImmunoCellular Therapeutics (OTCMKTS:IMUC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Insider & Institutional Ownership

0.1% of Wellness Center USA shares are held by institutional investors. 14.1% of Wellness Center USA shares are held by insiders. Comparatively, 3.3% of ImmunoCellular Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Wellness Center USA and ImmunoCellular Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

ImmunoCellular Therapeutics has lower revenue, but higher earnings than Wellness Center USA.

Volatility & Risk

Wellness Center USA has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, ImmunoCellular Therapeutics has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Wellness Center USA and ImmunoCellular Therapeutics, as reported by MarketBeat.com.

Profitability

This table compares Wellness Center USA and ImmunoCellular Therapeutics' net margins, return on equity and return on assets.

Summary

Wellness Center USA beats ImmunoCellular Therapeutics on 3 of the 5 factors compared between the two stocks.

ImmunoCellular Therapeutics (OTCMKTS:IMUC) and Kaya (OTCMKTS:KAYS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, valuation, earnings, profitability and institutional ownership.

Profitability

This table compares ImmunoCellular Therapeutics and Kaya's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares ImmunoCellular Therapeutics and Kaya's top-line revenue, earnings per share and valuation.

Kaya has higher revenue and earnings than ImmunoCellular Therapeutics.

Analyst Recommendations

This is a breakdown of current ratings for ImmunoCellular Therapeutics and Kaya, as provided by MarketBeat.

Volatility and Risk

ImmunoCellular Therapeutics has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. Comparatively, Kaya has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500.

Summary

ImmunoCellular Therapeutics beats Kaya on 3 of the 4 factors compared between the two stocks.

International Stem Cell (OTCMKTS:ISCO) and ImmunoCellular Therapeutics (OTCMKTS:IMUC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Valuation & Earnings

This table compares International Stem Cell and ImmunoCellular Therapeutics' revenue, earnings per share and valuation.

ImmunoCellular Therapeutics has lower revenue, but higher earnings than International Stem Cell.

Volatility & Risk

International Stem Cell has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, ImmunoCellular Therapeutics has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for International Stem Cell and ImmunoCellular Therapeutics, as reported by MarketBeat.com.

Profitability

This table compares International Stem Cell and ImmunoCellular Therapeutics' net margins, return on equity and return on assets.

Summary

ImmunoCellular Therapeutics beats International Stem Cell on 3 of the 4 factors compared between the two stocks.

ImmunoCellular Therapeutics (OTCMKTS:IMUC) and Intellipharmaceutics International (OTCMKTS:IPCIF) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Valuation and Earnings

This table compares ImmunoCellular Therapeutics and Intellipharmaceutics International's gross revenue, earnings per share and valuation.

ImmunoCellular Therapeutics has higher earnings, but lower revenue than Intellipharmaceutics International.

Analyst Recommendations

This is a summary of current ratings for ImmunoCellular Therapeutics and Intellipharmaceutics International, as provided by MarketBeat.com.

Volatility and Risk

ImmunoCellular Therapeutics has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500. Comparatively, Intellipharmaceutics International has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500.

Profitability

This table compares ImmunoCellular Therapeutics and Intellipharmaceutics International's net margins, return on equity and return on assets.

Summary

ImmunoCellular Therapeutics beats Intellipharmaceutics International on 3 of the 4 factors compared between the two stocks.

BriaCell Therapeutics (OTCMKTS:BCTXF) and ImmunoCellular Therapeutics (OTCMKTS:IMUC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, dividends, profitability and analyst recommendations.

Risk & Volatility

BriaCell Therapeutics has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Comparatively, ImmunoCellular Therapeutics has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500.

Insider & Institutional Ownership

0.1% of BriaCell Therapeutics shares are held by institutional investors. 3.3% of ImmunoCellular Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares BriaCell Therapeutics and ImmunoCellular Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for BriaCell Therapeutics and ImmunoCellular Therapeutics, as reported by MarketBeat.com.

Valuation and Earnings

This table compares BriaCell Therapeutics and ImmunoCellular Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Summary

ImmunoCellular Therapeutics beats BriaCell Therapeutics on 3 of the 4 factors compared between the two stocks.

FutureWorld (OTCMKTS:FWDG) and ImmunoCellular Therapeutics (OTCMKTS:IMUC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability.

Profitability

This table compares FutureWorld and ImmunoCellular Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations for FutureWorld and ImmunoCellular Therapeutics, as provided by MarketBeat.

Risk and Volatility

FutureWorld has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Comparatively, ImmunoCellular Therapeutics has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500.

Earnings and Valuation

This table compares FutureWorld and ImmunoCellular Therapeutics' revenue, earnings per share (EPS) and valuation.

Summary

ImmunoCellular Therapeutics beats FutureWorld on 1 of the 1 factors compared between the two stocks.